Abstract
Poor glycemic control in patients undergoing BMT is associated with non-relapse mortality. Impaired immune function and infection related to hyperglycemia, as well as increased morbidity and mortality associated with hypoglycemia and glucose variability have been demonstrated. Medications utilized in the BMT population; e.g. steroids and immunosuppressive agents, combined with the conditions of neutropenia and type II or steroid induced diabetes mellitus, necessitates well coordinated blood glucose management in order to improve overall patient outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
